Impact of MMP2 rs243865 and MMP3 rs3025058 Polymorphisms on Clinical Findings in Alzheimer’s Disease Patients
Table 2
Allele and genotype frequencies of MMP2 polymorphism rs243865 (-1306 C/T) in AD patients and controls.
SNP/model
Allele/genotype
AD subjects ()
Controls ()
Univariate analysis
Multivariate analysis
OR (95% CI)
OR (95% CI)
rs243865
C
252 (73.68%)
455 (73.86%)
—
—
T
90 (26.32%)
161 (26.14%)
0.95
1.01 (0.75-1.36)
—
—
Codominant
CC
98 (57.31%)
170 (55.19%)
1.00
1.00
CT
56 (32.75%)
115 (37.34%)
0.46
0.84 (0.56-1.27)
0.62
0.88 (0.57-1.34)
TT
17 (9.94%)
23 (7.47%)
1.28 (0.65-2.52)
1.25 (0.61-2.57)
Dominant
CC
98 (57.31%)
170 (55.19%)
1.00
1.00
CT+TT
73 (42.69%)
138 (44.81%)
0.65
0.92 (0.63-1.34)
0.76
0.94 (0.63-1.40)
Recessive
CC+CT
154 (90.06%)
285 (92.53%)
1.00
1.00
TT
17 (9.94%)
23 (7.47%)
0.35
1.37 (0.71-2.64)
0.44
1.32 (0.65-2.65)
Overdominant
CC+TT
115 (67.25%)
193 (62.66%)
CT
56 (32.75%)
115 (37.34%)
0.31
0.82 (0.55-1.21)
0.44
0.85 (0.56-1.29)
Abbreviations: CI: confidence interval; : number; OR: odds ratio. Allele and genotype frequencies are given as absolute numbers with percentages in parentheses. Univariate analysis is based on the Pearson chi-squared test. Multivariate analysis is adjusted for sex, age, and APOEε4 positivity. is considered statistically significant.
